Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Varsha Gandhi, PhD, on Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Jul
21
Today In Oncology
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
AMP Recognizes NCI Pathologist With Award for Excellence in Molecular Diagnostics
Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant
Long-Term Outcomes With SABR in Primary Kidney Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo